Impact Biomedical Inc
IBO
Detailliertes Diagramm anzeigen
0.533USD
+0.000+0.08%
Handelsschluss 11/04, 16:00（ET）Kurse um 15 Minuten verzögert
6.49MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+0.08%
5 Tage
-7.53%
1 Monat
-16.21%
6 Monate
-28.76%
Seit Jahresbeginn
-63.25%
1 Jahr
-80.41%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Impact Biomedical Inc
Währung: USD Aktualisiert: 2025-10-27Wichtige Einblicke
Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Impact Biomedical Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
0
Analysten
--
Aktuelles Rating
--
Kursziel
--
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Impact Biomedical Inc Highlights
HöhepunkteRisiko
Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.
high_profit_growth
high_profit_growth_desc%!(EXTRA string=0.00)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-0.17)
institutional_increasing_position
institutional_increasing_position_desc%!(EXTRA string=508.04K, string=15.77%)
Impact Biomedical Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Impact Biomedical Inc Informationen
Impact Biomedical Inc. is a human healthcare company and is a wholly owned subsidiary of DSS, Inc. The Company, through the utilization of its intellectual property rights, or through investment in, or through acquisition of companies in the bio health and biomedical fields, focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The Company, through its subsidiary, Global BioLife, Inc., focuses on research in four main areas: the Linebacker project, which develops a universal therapeutic drug platform; a new sugar substitute called Laetose; a multi-use fragrance called 3F (Functional Fragrance Formulation), which is a mosquito fragrance product; and Equivir/Nemovir, a blend of natural polyphenols designed as an antimicrobial medication.
BörsenkürzelIBO
UnternehmenImpact Biomedical Inc
CEOMr. Frank D. Heuszel, CPA
Websitehttps://www.impactbiomedinc.com/
Verwandte Finanzinstrumente
+1.15%
+0.32%
+1.85%
+0.38%
+0.93%
+1.66%
-1.75%
+0.13%
+0.78%
-1.46%
-1.88%
-1.02%
+2.61%
+1.01%
-0.93%
-0.64%
0.00%
-2.22%
-2.44%
-13.78%Beliebte Symbole
